Pęczek, P.; Leśniewski, M.; Mazurek, T.; Szarpak, L.; Filipiak, K.J.; Gąsecka, A.
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia. Life 2021, 11, 466.
https://doi.org/10.3390/life11060466
AMA Style
Pęczek P, Leśniewski M, Mazurek T, Szarpak L, Filipiak KJ, Gąsecka A.
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia. Life. 2021; 11(6):466.
https://doi.org/10.3390/life11060466
Chicago/Turabian Style
Pęczek, Piotr, Mateusz Leśniewski, Tomasz Mazurek, Lukasz Szarpak, Krzysztof J. Filipiak, and Aleksandra Gąsecka.
2021. "Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia" Life 11, no. 6: 466.
https://doi.org/10.3390/life11060466
APA Style
Pęczek, P., Leśniewski, M., Mazurek, T., Szarpak, L., Filipiak, K. J., & Gąsecka, A.
(2021). Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia. Life, 11(6), 466.
https://doi.org/10.3390/life11060466